PPIDT00402
Drug Information
| Name | Isatuximab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB14811 |
| Type | biotech |
| Indication | Isatuximab is indicated in combination with [pomalidomide] and [dexamethasone] for the treatment of multiple myeloma in adults who have received at least two prior therapies including [lenalidomide] and a proteasome inhibitor.[L12099] It is also indicated in combination [carfilzomib] and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.[L12099] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution, concentrate | Intravenous |
100 mg/5mL
|
| Injection, solution, concentrate | Intravenous |
20 MG/ML
|
| Injection, solution, concentrate | Intravenous |
500 mg/25mL
|
| Solution | Intravenous |
100 mg / 5 mL
|
| Solution | Intravenous |
500 mg / 25 mL
|
| Injection, solution | Intravenous |
100 mg/5ml
|
| Injection, solution | Intravenous |
500 mg/25ml
|